Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo

Insomnia Clinical Trial

Official title:

Investigation of Psycliomotor and Cognitive Residual Effects After Single Oral Doses of Zolpidem Tartrate Extended Release 12.5 mg and Eszopielone 3 mg Compared to Placebo in Healthy Young Volunteers, Using Plurazepam 30 mg As An External Comparator

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00283790
• Other study ID #: PM_L_0289
• Status: Completed
• Phase: Phase 4
• First received: January 27, 2006
• Last updated: April 1, 2008
• Start date: January 2006
• Est. completion date: April 2006

Study information

• Verified date: April 2008
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Investigation of Psychomotor and Cognitive Residual Effects of Single Oral Doses of Zolpidem Tartrate Extended Release 12.5 mg and Eszopiclone 3 mg Compared to Placebo in Healthy Young Volunteers, Using Flurazepam 30 mg as an External Comparator

Description:

This is a crossover study, with 4 different treatments (Ambien, Lunesta, placebo, and flurazepam). The flurazepam arm always comes last due to the long washout period associated with it. The other 3 arms are randomized.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: April 2006
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 45 Years

Eligibility

INCLUSION CRITERIA:

1. Healthy male and female subjects aged between 18 and 45 years.

2. Usual bedtime between 21:00 and 01:00

3. Body mass index (BMI) between 18 and 32 kg/m2.

4. Certified as healthy by a comprehensive clinical assessment (detailed medical history and a complete physical examination).

5. Laboratory tests within the normal range of the laboratory (hematology, biochemistry, urinalysis) or within the acceptable range per agreement between investigator and sponsor.

6. Negative urine pregnancy test for females (to be confirmed at screening and prior to every dose of study medication)

7. Women must use a medically acceptable form of contraception (steroidal contraceptive, double-barrier, or intra-uterine device) during the entire study period, or they must be surgically sterilized or post-menopausal. If abstinent, women must agree to use double-barrier contraception throughout the study period should they become sexually active.

8. Written informed consent signed

EXCLUSION CRITERIA:

1. Presence or history of clinically relevant cardiovascular, hepatic, pulmonary, gastrointestinal, renal, metabolic, hematological, neurologic or psychiatric disease, any acute infectious disease or signs of acute illness, and myasthenia gravis

2. Any disorder initiating or maintaining sleep such as Obstructive Sleep Apnea, Insomnia, Restless Leg Syndrome, Periodic Limb Movement Disorder, Circadian Rhythm Disorder and Parasomnia

3. Frequent headaches and/or migraine, recurrent nausea and/or vomiting (more than twice a month).

4. Symptomatic hypotension, whatever the decrease of blood pressure, or asymptomatic postural hypotension defined by a decrease in SBP equal to or greater than 20 mmHg within two minutes when changing from the supine to the standing position.

5. History of hypersensitivity to zolpidem, eszopiclone, or flurazepam.

6. Use of any medication within one month prior to study start, except occasional use of acetaminophen or ibuprofen.

7. History of drug abuse during prior twelve months

8. Excessive consumption of xanthine-based beverages (more than 6 cups or glasses per day) or unable to stop consumption during the overnight study periods.

9. Inability to communicate or cooperate with the investigator because of a language problem, poor mental status, or impaired cerebral status.

10. Positive results of urine drug screen testing (amphetamines, benzodiazepines, cannabis, barbiturates, cocaine, opiates, antidepressants).

11. Any use of dietary, herbal, and/or fitness/body-building supplements (with the exception of vitamins)

12. Current use of tobacco products including cigarettes, cigars, pipes, or chewing tobacco, current participation in a smoking cessation program, or discontinuation of smoking within 3 months prior to screening

13. Subject is currently participating in another clinical trial with an investigation product/device (or within 30 days of screening).

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Insomnia

Intervention

Drug:
• zolpidem tartrate

Locations

Country	Name	City	State
United States	Sanofi-Aventis	Bridgewater	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Psychometric testing:
Primary	Critical Flicker Fusion (CFF)
Primary	Choice Reaction Time (CRT)
Primary	Immediate and Delayed Recall of Supraspan Word Lists (WRI and WRD)
Primary	Compensatory Tracking Task (CTT)
Primary	Digit Symbol Substitution Test (DSST)
Secondary	Efficacy Measures:
Secondary	Sleep measures from Morning Sleep Questionnaire
Secondary	Residual Effects of Zolpidem Tartrate Extended Release and Eszopiclone Vs Placebo
Secondary	Leeds Sleep Evaluation Questionnaire (LSEQ)
Secondary	Bond & Lader (B&L) Visual Analog Scale
Secondary	Health Outcome Measures
Secondary	Sleep Treatment Questionnaire